20/20 Biolabs

As of June 30, 2026, cash and cash equivalents were 4.55 million, aided by 6.0 million Series E preferred proceeds in 1H26; total liabilities were 2.96 million, and redeemable Series E preferred was 1.54 million. TTM free cash flow through Q2 2026 is approximately −2.8 million, implying limited runway without further external capital.

The company eliminated convertible notes by exchanging into Series E but remains exposed to preferred dividends, MFN and warrant features that can be dilutive. A July 2026 Nasdaq bid‑price deficiency notice adds listing risk. Overall balance sheet resilience is weak for adverse scenarios.